Why the Certificate of Analysis Matters
When a vial of synthetic research peptide arrives in the laboratory, the Certificate of Analysis (COA) is the single most important document accompanying it. A COA is the supplier's formal record of the analytical tests performed on a specific batch of peptide, and it provides objective, batch-specific data rather than generic product claims. Understanding how to read and critically evaluate a COA allows researchers to make informed decisions about whether a given lot is suitable for their experimental application, how to handle the material, and how to interpret downstream results accurately.
Not all COAs are equally comprehensive. A rigorous supplier will include results from multiple orthogonal analytical techniques. The sections below describe each major component of a well-constructed peptide COA and explain what researchers should look for in each.
Lot and Catalog Identification
Every COA should begin with clear identifying information that links the document unambiguously to a specific batch of material. Key fields include:
- Catalog or product number: The supplier's unique identifier for the peptide sequence and any modifications.
- Lot or batch number: A unique alphanumeric code for the specific synthesis run. This is critical for traceability; if a research group identifies an anomaly in results, the lot number enables the supplier to retrieve full manufacturing and QC records.
- Peptide sequence: The full amino acid sequence written in standard one-letter or three-letter code, including any N- or C-terminal modifications (e.g., acetylation, amidation) and any non-standard residues or post-translational modification mimetics.
- Molecular formula and theoretical molecular weight: These should be consistent with the stated sequence and modifications, and researchers can independently verify them using publicly available peptide calculators.
Before examining any analytical data, confirm that the lot number on the vial label matches the lot number on the COA. A mismatch invalidates the document entirely for that vial.
Purity by Reverse-Phase HPLC
Purity is perhaps the single most referenced value on a peptide COA, and it is almost universally determined by reverse-phase high-performance liquid chromatography (RP-HPLC). The technique separates peptide species by hydrophobicity, and the UV absorbance trace (typically at 214 nm or 220 nm, which reflects peptide bond absorbance) is integrated to calculate relative peak areas.
The reported purity percentage represents the area of the main peptide peak as a fraction of the total integrated area. A value of ≥95% is a commonly accepted threshold for many biochemical assay applications, though certain sensitive assays may require ≥98%. Values between 85–95% may be acceptable for initial exploratory screening but should be factored into experimental design, particularly when dose–response linearity or receptor-binding stoichiometry is important.
Researchers should look for:
- The actual chromatogram or trace image: A single dominant peak with minor flanking impurities is expected. Broad, shouldered, or multiple major peaks warrant caution and follow-up inquiry with the supplier.
- Column and gradient conditions: These determine whether the separation is appropriate for the peptide's physicochemical properties. A gradient that is too shallow may co-elute impurities with the main peak, artificially inflating purity.
- Detection wavelength: 214 nm is standard; some suppliers use 220 nm or 254 nm. The choice affects sensitivity to different impurity classes.
Molecular Mass Confirmation by Mass Spectrometry
HPLC purity data alone cannot confirm molecular identity; a contaminant at the same retention time as the target peptide would be invisible to purity analysis. Mass spectrometry (MS) provides identity confirmation by measuring the mass-to-charge ratio (m/z) of ionized species.
Most peptide COAs report results from electrospray ionization mass spectrometry (ESI-MS) or matrix-assisted laser desorption/ionization time-of-flight MS (MALDI-TOF). The COA should state:
- Theoretical monoisotopic or average molecular weight: Calculated from the molecular formula.
- Observed molecular weight: Measured from the spectrum. Agreement within ±0.5 Da (for monoisotopic masses of smaller peptides) or within 0.1% of average mass (for larger peptides) is generally acceptable, though tighter tolerances are achievable with modern instruments.
- Observed charge states: For ESI-MS, multiply charged ions ([M+nH]n+) are expected; the COA should show at least one confirmed charge state with the corresponding m/z value.
A discrepancy between theoretical and observed mass may indicate incorrect sequence, missed deprotection, unwanted oxidation (e.g., methionine or tryptophan side chains), or incomplete modification. Any such discrepancy should be discussed with the supplier before the material is used in experiments.
Water Content and Net Peptide Content
Lyophilized peptides are hygroscopic and routinely contain residual water and counterion salts (typically trifluoroacetate from RP-HPLC purification, or acetate if salt-exchanged). The gross weight stated on the vial is not equivalent to the net peptide content.
Reputable suppliers determine water content by Karl Fischer titration and may report counterion content by ion chromatography or NMR. The net peptide content (sometimes called peptide content percentage) is the mass fraction attributable solely to the peptide molecule. A vial labeled as 5 mg with 70% net peptide content contains approximately 3.5 mg of actual peptide.
This value is essential for preparing accurate stock solutions and for all quantitative experimental work. Researchers who ignore net peptide content and assume 100% purity will systematically underestimate the actual peptide concentration in their working solutions.
Additional Analytical Parameters
Depending on the peptide and supplier capabilities, COAs may include additional data:
- Amino acid analysis (AAA): Acid hydrolysis followed by chromatographic quantitation of individual amino acids. Provides independent sequence and content verification.
- Optical rotation or chiral purity: Relevant for peptides where D-amino acid incorporation or racemization during synthesis is a concern.
- Endotoxin testing: Limulus amebocyte lysate (LAL) assay results are important for peptides intended for use in cell-based assays where lipopolysaccharide contamination could confound biological readouts.
- Solubility testing: Some suppliers document observed solubility under defined buffer conditions, which is valuable for experimental planning.
Storage Conditions and Expiry
A COA should specify recommended storage conditions (e.g., −20 °C or −80 °C, desiccated, protected from light) and, where applicable, an expiry or retest date. These conditions are determined based on the chemical stability of the specific sequence and any modifications. Disregarding storage recommendations can lead to degradation—including oxidation, deamidation, or aggregation—that is not apparent from purity data generated at the time of manufacture.
Interpreting the COA in Context
A COA reflects the quality of the material at the time of analysis. Subsequent improper storage, repeated freeze–thaw cycles, or dissolution in incompatible solvents can degrade peptide quality independent of what the COA certifies. For critical experiments, researchers should consider re-analyzing received material by in-house HPLC or MS, particularly when working with sensitive biological assays or when lot-to-lot consistency is essential.
Cross-referencing purity, mass confirmation, and net peptide content together—rather than relying on a single metric—gives a complete picture of material quality. When any parameter is missing from a supplier's COA, it is appropriate and advisable to request the underlying analytical data before proceeding.
For research use only. The information presented in this article is intended solely for qualified researchers working in laboratory settings. Research peptides supplied by Pepitiva Biolabs are not intended for human or veterinary use, clinical application, or therapeutic purposes.